Nevirapine Aurobindo

Nevirapine, the active ingredient in Nevirapine Aurobindo, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It is used in the treatment of HIV‑1 infection in adults and adolescents. GNH USA supplies Nevirapine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication that targets the HIV‑1 reverse transcriptase pathway. - HIV‑1 infection: reduces viral replication and helps restore immune function in infected individuals.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: significant liver injury, potentially leading to jaundice. - Severe rash: extensive skin involvement. - Hypersensitivity reactions: including fever and eosinophilia. - Hematologic abnormalities: such as neutropenia or anemia. - Pancreatitis: inflammation of the pancreas.

When prescribing Nevirapine, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic liver enzymes. - Skin assessment: watch for rash or signs of severe cutaneous reactions. - Pregnancy considerations: evaluate risks versus benefits before use. - Drug interactions: review concomitant medications for potential interactions. - Adherence counseling: emphasize importance of consistent dosing. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Nevirapine can affect the metabolism of other drugs, requiring careful review.

Major Interactions (Avoid): - Rifampicin: may reduce nevirapine plasma levels, compromising efficacy. - St. John’s wort: induces metabolism, lowering drug exposure. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect, monitor INR. - Oral contraceptives: reduced effectiveness, consider alternative contraception. - Efavirenz: combined use may increase hepatotoxicity risk. - Fluconazole: may increase nevirapine levels, monitor liver function.